Garg Pushkal (CIK 0001829252)

Latest company ownership

Shares held
681
Last filed at
Oct 3, 2025
Confidence Score
52.1
2025Q4
Confidence Score History
2022Q3 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Oct 1, 2025 Oct 3, 2025 ALNYLAM PHARMACEUTICALS, INC. EVP Chief R&D Sell 48.8 - 0.00% $2.7M
Aug 15, 2025 Aug 19, 2025 ALNYLAM PHARMACEUTICALS, INC. EVP Chief R&D Sell 48.8 - 0.00% $1.3M
Mar 21, 2025 Mar 25, 2025 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 15.0 -9,766 -19.19% $2.9M
Mar 3, 2025 Mar 5, 2025 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 97.5 +11,580 84.88% $621.2K
Feb 27, 2025 Mar 3, 2025 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 42.5 -935 -6.41% $226K
Feb 13, 2025 Feb 18, 2025 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 51.3 - 0.00% $787.9K
Jan 27, 2025 Jan 29, 2025 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 2.5 -52,592 -80.59% $15M
Dec 12, 2024 Dec 13, 2024 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 26.3 -1,752 -9.66% $439.8K
Nov 25, 2024 Nov 27, 2024 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 97.5 +1,752 10.69% $422.1K
Jun 24, 2024 Jun 26, 2024 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 97.5 +2,192 15.55% $485.8K
Feb 27, 2024 Feb 29, 2024 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 42.5 -574 -5.79% $89.1K
Feb 15, 2024 Feb 20, 2024 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 95.0 +2,987 59.43% $193.7K
Aug 3, 2023 Aug 7, 2023 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 48.8 - 0.00% $1.4M
Apr 26, 2023 Apr 28, 2023 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 51.3 - 0.00% $846.5K
Mar 3, 2023 Mar 7, 2023 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 5.0 -18,072 -78.24% $3.6M
Aug 3, 2022 Aug 5, 2022 ALNYLAM PHARMACEUTICALS, INC. CMO & EVP Dev & Med Affairs Sell 97.5 +6,225 52.43% $974.2K